|

Clinical Trials in Kansas

521 recruiting studies across 36 cities, spanning 17 conditions.

Browse by Condition

All Trials in Kansas

Phase
Trial Phase Location
Collection and Storage of Tissue and Blood Samples From Patients With Cancer—Chanute
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung CancerPhase 2/3Chanute
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus PembrolizumabPhase 3Chanute
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7Phase 2/3Chanute
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus TrastuzumabPhase 3Chanute
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast CancerPhase 3Chanute
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLLPhase 3Chanute
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])Phase 3Chanute
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsPhase 2Chanute
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE TrialPhase 3Chanute
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive MeningiomasPhase 2Chanute
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac ToxicityPhase 3Coffeyville
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic AlterationsPhase 2Colby
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)Phase 3El Dorado
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes MellitusPhase 3El Dorado
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes MellitusPhase 3El Dorado
A Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies—El Dorado
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular DiseasePhase 3El Dorado
Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes MellitusPhase 2El Dorado
HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 DiabetesPhase 2El Dorado
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With DapagliflozinPhase 3El Dorado
A First-in-Human Study of MEN2312 in Adults With Advanced Breast CancerPhase 1Fairway
A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)Phase 1/2Fairway
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations DiseasePhase 1Fairway
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)Phase 2Fairway
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid TumorsPhase 1/2Fairway
A Study With NKT3964 for Adults With Advanced/Metastatic Solid TumorsPhase 1Fairway
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)Phase 2Fairway
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)Phase 2Fairway
A Study of IBI363 in Subjects with Advanced Solid MalignanciesPhase 2Fairway
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular LymphomaPhase 1Fairway
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal AdenocarcinomaPhase 2Fairway
A Study of Sigvotatug Vedotin in Advanced Solid TumorsPhase 1Fairway
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)Phase 1/2Fairway
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian CancerN/AFairway
A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)Phase 1Fairway
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AMLPhase 1Fairway
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder CancerPhase 1Fairway
A Trial to Evaluate Safety, Tolerability, and Preliminary Efficacy of Misetionamide (GP-2250) as Monotherapy or in Combination With GemcitabinePhase 1Fairway
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 MutationPhase 2Fairway
APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AMLPhase 1Fairway
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)Phase 2/3Fairway
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic AdenocarcinomaPhase 3Fairway
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE TrialPhase 3Fairway
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AMLPhase 2Fairway
Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal CancerPhase 1Fairway
Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLCPhase 1/2Fairway
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)Phase 2Fairway
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)Phase 2Fairway
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)Phase 2Fairway
Cost Communication and Financial Navigation in Cancer Patients (COSTCOM)N/AFairway
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Myasthenia GravisN/AFairway
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous PolypsN/AFairway
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)Phase 2Fairway
Metarrestin (ML-246) in Subjects With Metastatic Solid TumorsPhase 1Fairway
PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 DiabetesPhase 4Fairway
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AMLPhase 3Fairway
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBCPhase 2Fairway
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AMLPhase 3Fairway
Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02Phase 1Fairway
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid TumorsPhase 1/2Fairway
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment DelaysN/AFairway
SynKIR-310 for Relapsed/Refractory B-NHLPhase 1Fairway
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)Phase 2Fairway
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)Phase 2Fairway
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)Phase 2Fairway
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVOPhase 1Fairway
Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian CancerPhase 1Fairway
Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal CancerPhase 1Fairway
Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck CancerPhase 1Fairway
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or AstrocytomaPhase 1Fairway
Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable CancersPhase 1Fairway
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung CancerPhase 1/2Fairway
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and EffectivenessPhase 1/2Fairway
Testing the Effects of a Text Message Caregiver Support Intervention for LatinosN/AFairway
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC TrialPhase 3Fairway
Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC GenePhase 1/2Fairway
Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast CancerPhase 2Fairway
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM StudyPhase 2Fairway
Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC—Fairway
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)Phase 2Fairway
ZZ06 in Adult Patients With Advanced Solid Tumor MalignanciesPhase 1Fairway
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain MetastasesPhase 2Garden City
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)Phase 3Garden City
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection—Garden City
Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects—Garden City
Colon Adjuvant Chemotherapy Based on Evaluation of Residual DiseasePhase 2/3Garden City
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable TreatmentPhase 3Garden City
Comparing Telephone Symptom Monitoring Interventions for Managing Symptoms and Psychological Distress During Oral Anti-Cancer TreatmentN/AGarden City
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE TrialPhase 3Garden City
Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer SurvivorsPhase 3Garden City
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25Phase 3Garden City
Family Communications After Genetic TestingN/AGarden City
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors—Garden City
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic LeukemiaPhase 2Garden City
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic LeukemiaPhase 3Garden City
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering MyelomaPhase 3Garden City
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung CancerPhase 3Garden City
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone SurgeryPhase 2Garden City
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel CancersPhase 2Garden City
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast CancerN/AGarden City
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid CancerPhase 3Garden City
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL StudyPhase 3Garden City
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian CancerPhase 3Garden City
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 ChangePhase 2Garden City
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER StudyPhase 3Garden City
Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With CancerN/AGarden City
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract CancerPhase 2/3Garden City
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine TumorsPhase 2Garden City
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET ImagingPhase 3Garden City
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With CancerPhase 3Garden City
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric AdenocarcinomaPhase 3Garden City
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial CancerPhase 3Hays
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE TrialPhase 2/3Hays
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast CancerPhase 3Hays
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics—Hays
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular LymphomaPhase 3Hays
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT TrialPhase 3Hays
Reaching Rural Cancer Survivors Who Smoke Using Text-Based ProgramPhase 3Hays
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell LymphomaPhase 3Hays
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low TrialPhase 3Hays
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous TreatmentPhase 3Hays
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE TrialPhase 3Hays
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN StudyPhase 2/3Hays
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland CancersPhase 2Hays
Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry—Hays
Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled CorticosteroidsPhase 2Hutchinson
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular EventsPhase 3Hutchinson
Prospective Study to Assess a Diagnostic Aid for Cancer—Hutchinson
Shield Post-Approval Study Protocol—Hutchinson
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)Phase 3Hutchinson
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal TumorsPhase 3Kansas City
A First-in-Human Study of YL217 in Patients With Advanced Solid TumorsPhase 1Kansas City
A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary CholangitisPhase 3Kansas City
A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa—Kansas City
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic MalignanciesPhase 1Kansas City
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's DiseasePhase 2Kansas City
A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)Phase 2Kansas City
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant DepressionN/AKansas City
A Study Assessing Long-Term Safety and Effectiveness in Treatment Management of Atrial Fibrillation With VARIPULSE Catheter SystemN/AKansas City
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)Phase 3Kansas City
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple MyelomaPhase 3Kansas City
A Study of Buntanetap in Participants With PDPhase 2/3Kansas City
A Study of CDX-622 in Participants With Mild to Moderate AsthmaPhase 1Kansas City
A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's DiseasePhase 4Kansas City
A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic SyndromesPhase 1Kansas City
A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic AsthmaPhase 2Kansas City
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )Phase 1Kansas City
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia GravisPhase 3Kansas City
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 DiabetesPhase 3Kansas City
A Study of Orelabrutinib in Patients With Primary Progressive Multiple SclerosisPhase 3Kansas City
A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate CancerPhase 1Kansas City
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid TumorsPhase 1/2Kansas City
A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 DiabetesPhase 2Kansas City
A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's DiseasePhase 2/3Kansas City
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure PatientsPhase 3Kansas City
A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative NeoplasmsPhase 1Kansas City
A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor FluctuationsPhase 2Kansas City
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus ErythematosusPhase 3Kansas City
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's DiseasePhase 3Kansas City
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASHPhase 3Kansas City
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple SclerosisPhase 3Kansas City
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis SpasticityPhase 2Kansas City
A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.Phase 4Kansas City
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)Phase 3Kansas City
A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's DiseasePhase 3Kansas City
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)Phase 3Kansas City
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune DiseasePhase 1Kansas City
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary DiseasePhase 2/3Kansas City
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe AsthmaPhase 2Kansas City
A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)Phase 2Kansas City
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the HeartPhase 3Kansas City
A Tailored Medication Adherence-Promotion Intervention for Adolescents and Young Adults With CancerN/AKansas City
ALLIANCE: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart ValveN/AKansas City
AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe EpilepsyPhase 1/2Kansas City
Abatacept in Immune Checkpoint Inhibitor MyocarditisPhase 3Kansas City
Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast CancerPhase 2Kansas City
Adapting RDAD for DSN/AKansas City
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.Phase 3Kansas City
Analysis of Cutaneous Phosphorylated Alpha-Synuclein to Identify Patients at Risk of Progressing From Essential Tremor to Parkinson's Disease—Kansas City
Anticoagulation in ICH Survivors for Stroke Prevention and RecoveryPhase 3Kansas City
Assessing the Association Between WBCT PFJ Morphological Metrics and Knee Symptoms—Kansas City
Assessment of CCM in HF With Higher Ejection FractionN/AKansas City
BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHLPhase 1Kansas City
Bladder Cancer Longitudinal Biorepository for Development of Novel Therapeutics/Biomarkers—Kansas City
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)Phase 3Kansas City
Blue Light Cystoscopy With Cysview® Registry—Kansas City
Brain Outcomes With Lifestyle Change in Down SyndromeN/AKansas City
Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3N/AKansas City
CCM OPEN HF Registry—Kansas City
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALLPhase 2Kansas City
Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPDPhase 2Kansas City
Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier—Kansas City
Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral NeuropathyPhase 3Kansas City
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL AmyloidosisPhase 3Kansas City
Comparing Hypo-fractionated Intensity- Modulated Radiation Therapy to Standard- Fractionated IMRT Along With Chemotherapy and Immunotherapy for Non-Small Cell Lung CancerPhase 2Kansas City
Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Advanced Head and Neck Cancer Who Cannot Receive CisplatinPhase 3Kansas City
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity CancerPhase 2/3Kansas City
Comparing Telehealth-Delivered CBT-I to Web-Based CBT-I to Enhance Sleep, Reduce Fatigue, and Promote NeuroprotectionPhase 2Kansas City
Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage MelanomaPhase 3Kansas City
Comparision of Aerobic Exercise to Aerobic Plus Yoga Exercise for Weight Loss in Adults With Overweight or Obesity.N/AKansas City
Conformal Ablative Radiotherapy in Older Women (CARMEN) With Breast Cancer Undergoing Non-Operative ManagementN/AKansas City
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCLPhase 2Kansas City
Cooking Skills to Improve Long-Term Weight Loss in Young Adults With Intellectual DisabilitiesN/AKansas City
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)Phase 3Kansas City
Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease—Kansas City
DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting—Kansas City
Depemokimab Asthma Imaging and Bronchoscopy Sub-StudyPhase 3Kansas City
Dry Needling in Multiple SclerosisN/AKansas City
ELEVATE-HFpEF Clinical StudyN/AKansas City
ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in AdultsPhase 2Kansas City
Early Feasibility Study - Edwards APTURE Transcatheter Shunt SystemN/AKansas City
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACSPhase 3Kansas City
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.Phase 3Kansas City
Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder CancerPhase 2Kansas City
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)Phase 3Kansas City
Efficacy of the COronary SInus Reducer in Patients With Refractory Angina IIN/AKansas City
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic PhenotypePhase 3Kansas City
Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and SarcomasPhase 1/2Kansas City
Encore PFO Closure Device - The PerFOrm TrialN/AKansas City
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With AsthmaPhase 3Kansas City
Evaluation of Ventilation Defects Downstream of Mucus Plugs in Patients With Muco-Obstructive Lung Disease—Kansas City
Exosomes in Rectal Cancer—Kansas City
Fabry Disease Registry & Pregnancy Sub-registry—Kansas City
Feasibility and Safety of Ketamine for Suicidal Patients in the Emergency DepartmentPhase 1Kansas City
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE TrialPhase 2Kansas City
HF2 Registry - Hemodynamic Frontiers in Heart Failure Registry—Kansas City
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube CancerPhase 3Kansas City
High Risk Breast Clinic: Protocol for Women at Increased Risk for Developing Breast Cancer—Kansas City
HoLEP Prior to Radiation Therapy for Patients With LUTS/Retention and Concurrent Prostate CancerN/AKansas City
Human/Machine Interface: What the HeartMate 3 ® Device Tells Us About the Future—Kansas City
Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary DiseasePhase 1Kansas City
Implementing the NYU Electronic Patient Visit Assessment (ePVA) for Head and Neck Cancer In Rural and Urban PopulationsN/AKansas City
Individualizing Treatment for Asthma in Primary Care (Full Study)Phase 4Kansas City
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical CancerPhase 3Kansas City
Intravenous Ascorbate Plus Gemcitabine/Carboplatin: A Novel and Cost-Effective Alternative With Evident Efficacy in Patients With Muscle Invasive Bladder CancerPhase 2Kansas City
Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart FailureN/AKansas City
Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's EsophagusPhase 2Kansas City
Ivosidenib as Post-HSCT Maintenance for AMLPhase 2Kansas City
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung CancerPhase 3Kansas City
Knee Osteoarthritis Treatment With Zilretta vs. Kenalog in the Context of Type II DiabetesPhase 4Kansas City
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-NaïvePhase 1/2Kansas City
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver FibrosisPhase 3Kansas City
LaserEn: SOLTIVE™ Thulium Laser Fiber En Bloc Resection of Bladder Tumors—Kansas City
Lead-212 PSV359 Therapy for Patients With Solid TumorsPhase 1/2Kansas City
Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk ReductionPhase 2Kansas City
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)Phase 3Kansas City
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and ObesityPhase 3Kansas City
Metabolism Evaluation Through Resting Indirect Calorimetry in Bladder Cancer (METRICS)—Kansas City
Metformin for People With CFRD on CFTR Modulator Therapy to Improve Ion Channel FunctionPhase 2Kansas City
Mitigating the Pro-inflammatory Phenotype of ObesityPhase 1Kansas City
Muscle and Movement With Anti-Obesity MedicationsN/AKansas City
NLit and Outcomes in HNC Survivor-Caregiver Dyads—Kansas City
Obeticholic Acid for Prevention in Barrett's EsophagusPhase 2Kansas City
Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry—Kansas City
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted TherapyPhase 2/3Kansas City
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung CancerPhase 1Kansas City
PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort—Kansas City
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and IIIN/AKansas City
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.Phase 3Kansas City
Pancreatic Cancer Early Detection Consortium—Kansas City
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)—Kansas City
Phase 3 Trial of eRapa in Patients With Familial Adenomatous PolyposisPhase 3Kansas City
Prevail Global StudyN/AKansas City
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products—Kansas City
Product Surveillance Registry—Kansas City
Pulmonary Hypertension Biorepository and Registry—Kansas City
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical IllnessesPhase 2Kansas City
RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia GravisPhase 1/2Kansas City
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus ErythematosusPhase 1/2Kansas City
REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE—Kansas City
Registry Study for Radiation Therapy Outcomes—Kansas City
Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)—Kansas City
Rural Alliance for Diabetes PreventionN/AKansas City
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)Phase 3Kansas City
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory LymphomaPhase 1Kansas City
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid LeukemiaPhase 1Kansas City
Safety of MT-401-OTS in Patients With Relapsed AML or MDSPhase 1Kansas City
Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations—Kansas City
Slow Heart Registry of Fetal Immune-mediated High Degree Heart Block—Kansas City
Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve ReplacementN/AKansas City
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate CancerPhase 3Kansas City
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPCPhase 3Kansas City
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection FractionPhase 3Kansas City
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)Phase 2Kansas City
Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast CancerPhase 1Kansas City
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive DisorderPhase 3Kansas City
Study of Oral MRT-2359 With Apalutamide in Prostate CancerPhase 2Kansas City
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction CancerPhase 3Kansas City
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.Phase 3Kansas City
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.Phase 3Kansas City
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal SarcomaPhase 3Kansas City
Surgical Thromboprophylaxis Practices in Oncology Patients Within the NCORP Network, STOP-VTE Study—Kansas City
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)Phase 3Kansas City
TERPS Trial for de Novo Oligometastic Prostate CancerPhase 2Kansas City
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With CardiomyopathyPhase 3Kansas City
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT TrialPhase 2Kansas City
Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated GlioblastomaPhase 3Kansas City
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain CancerPhase 3Kansas City
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaPhase 2Kansas City
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic CancerPhase 3Kansas City
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM TrialPhase 3Kansas City
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate CancerPhase 3Kansas City
Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple MyelomaPhase 1Kansas City
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell CarcinomaPhase 2Kansas City
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial ChemotherapyPhase 3Kansas City
Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck CancerPhase 2Kansas City
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung CancerPhase 3Kansas City
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck CancerPhase 2Kansas City
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC TrialPhase 2Kansas City
The Fourth Left Atrial Appendage Occlusion StudyN/AKansas City
To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of TreatmentPhase 2Kansas City
Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.N/AKansas City
Treatment of Participants With Primary or Secondary Progressive Multiple SclerosisPhase 1/2Kansas City
Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart FailureN/AKansas City
Trial-Ready Cohort-Down Syndrome (TRC-DS)—Kansas City
Using Microbiome to Predict Durvalumab Toxicity in Post- Concurrent Chemoradiation Therapy (CCRT) NSCLC Patients—Kansas City
Vitamin D for Prostate Endocrine TherapyPhase 3Kansas City
Zilucoplan for Severe gMG ExacerbationsPhase 3Kansas City
vGRID SBRT: A Phase I Clinical Trial in Unresectable or Metastatic HCCN/AKansas City
A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia GravisPhase 2/3Lawrence
Measuring Surgical Recovery After Radical Cystectomy—Lawrence
Optimizing a Sensor-Enabled mHealth Intervention for Adolescents With Suboptimal Asthma ControlN/ALawrence
Parkinson's Foundation PD GENEration Genetic Registry—Lawrence
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)Phase 3Lawrence
The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry—Lawrence
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEFPhase 3Leavenworth
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung CancerPhase 3Leawood
Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening—Leawood
MultiCenter IDE Study of the PEEK-OPTIMA™ Femoral Component vs a CoCr Alloy TKA Femoral Component of Similar DesignN/ALeawood
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)Phase 3Lenexa
A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or EndometriosisPhase 3Lenexa
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus InfectionPhase 1Lenexa
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or OverweightPhase 3Lenexa
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and FatiguePhase 2/3Lenexa
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)Phase 3Lenexa
Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular EdemaPhase 2/3Lenexa
Promoting Active Therapy: Path to WellnessPhase 2Manhattan
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal CancerPhase 3Merriam
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate CancerPhase 1Merriam
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint InhibitorPhase 3Merriam
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose WeightPhase 3Newton
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary DiseasePhase 3Newton
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or OverweightPhase 3Newton
Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to CagrisemaPhase 3Newton
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve StenosisPhase 2Overland Park
A Phase 2b Clinical Trial of YN001 in Adults With Coronary AtherosclerosisPhase 2Overland Park
A Study of Dotinurad Versus Allopurinol in Participants With GoutPhase 3Overland Park
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib TherapyPhase 3Overland Park
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive SymptomsPhase 4Overland Park
A Study to Evaluate the Efficacy, PK, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently Responsive to Dopaminergic TherapyPhase 2Overland Park
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)Phase 3Overland Park
Clinical and Healthcare Outcomes From Real-World Use in the United States of a Companion AI During AF Ablation—Overland Park
Coherent Sine Burst Electroporation (CSE) Ablation System US IDE Study for Patients With Atrial FibrillationN/AOverland Park
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant DiseasePhase 2Overland Park
HER2-positive Breast Cancer Registry—Overland Park
HS Students Mandatory Universal Student Instruction in CPR Appraised Learning- Is the Mandate Working?—Overland Park
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular InterventionPhase 4Overland Park
Integrated Cancer Repository for Cancer Research—Overland Park
Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of BonePhase 3Overland Park
Long-Term Outcomes of LAA Contrast Flow in CT Scans After Endocardial LAA Closure: The CF-CT Registry—Overland Park
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous MelanomaN/AOverland Park
Observational Study to Examine the Procedural and Outcomes of AF Ablation Assisted by STAR Apollo™ Mapping System—Overland Park
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography TrialPhase 3Overland Park
Phase 2/3 Study of Participants With Recurrent Pericarditis Evaluating the Efficacy and Safety of KPL-387Phase 2/3Overland Park
Role of Novel ILR in the Management of PVCs—Overland Park
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety DisorderPhase 2Overland Park
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic AlterationsPhase 1/2Overland Park
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of UblituximabPhase 3Overland Park
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHLPhase 2Overland Park
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell LymphomaPhase 2Overland Park
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.Phase 3Overland Park
Tracking Results of Ablations to Combat AF Registry Generation 2—Overland Park
Use of 4D-ICE in Conjunction With TEE for Left Atrial Appendage ClosureN/AOverland Park
Vascular Closure With a Device Compared to Manual Compression After Atrial Fibrillation Ablation: The LockeT II StudyN/AOverland Park
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)—Roeland Park
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple SclerosisPhase 3Roeland Park
Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter DefibrillatorPhase 4Shawnee Mission
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASHPhase 3Topeka
A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic PainPhase 2Topeka
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASHPhase 3Topeka
A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 DiabetesPhase 2Topeka
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASHPhase 3Topeka
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)Phase 3Topeka
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 DiabetesPhase 3Topeka
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly IncretinPhase 3Topeka
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 DiabetesPhase 3Topeka
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 ObesityPhase 3Topeka
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)Phase 3Topeka
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or OverweightPhase 2Topeka
A Study to Investigate the Safety and Efficacy of Efimosfermin Alfa Compared With Placebo in Adult Participants With Alcohol-related Liver Disease (ALD)Phase 2Topeka
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver DiseasePhase 2Topeka
AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes MedicationsPhase 3Topeka
DESTINY-PANTUMOUR04—Topeka
E-Mindfulness Approaches for Living After Breast CancerPhase 3Topeka
Pan-tumor MRD Study—Topeka
A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid TumorsPhase 1/2Westwood
A Long-term Study for Participants Previously Treated With Ciltacabtagene AutoleucelPhase 4Westwood
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)—Westwood
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)—Westwood
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell TransplantationPhase 2Westwood
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell MalignanciesPhase 1/2Westwood
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)Phase 3Westwood
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic CancerPhase 1Westwood
A Study of ASP3082 in Adults With Advanced Solid TumorsPhase 1Westwood
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung CancerPhase 2Westwood
A Study of BG-C477 in Participants With Advanced Solid TumorsPhase 1Westwood
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell CarcinomaPhase 3Westwood
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung CancerPhase 3Westwood
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple MyelomaPhase 3Westwood
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast CancerPhase 1/2Westwood
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial CancerPhase 1/2Westwood
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate CancerPhase 3Westwood
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric CancerPhase 3Westwood
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid TumorsPhase 1Westwood
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)Phase 3Westwood
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative NeoplasmsPhase 1Westwood
A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)Phase 2Westwood
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)Phase 3Westwood
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaPhase 3Westwood
A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their BladderPhase 2Westwood
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell TherapyPhase 3Westwood
A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell MalignanciesPhase 1/2Westwood
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung CancerPhase 1/2Westwood
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.Phase 1/2Westwood
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal MalignanciesPhase 1/2Westwood
DALY II USA/ MB-CART2019.1 for DLBCLPhase 2Westwood
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine CancersPhase 2Westwood
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)—Westwood
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract CancerPhase 3Westwood
Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell MalignanciesPhase 1Westwood
Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant CyclophosphamidePhase 1Westwood
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCCPhase 2/3Westwood
First-in-Human Study of DS-3939a in Participants With Advanced Solid TumorsPhase 1/2Westwood
GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCCPhase 1/2Westwood
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerPhase 2Westwood
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic LeukemiaPhase 1/2Westwood
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian CancerPhase 2Westwood
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLCPhase 3Westwood
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU—Westwood
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T CellsPhase 2/3Westwood
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCTPhase 3Westwood
Pan Tumor Rollover StudyPhase 2Westwood
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid TumorsPhase 1Westwood
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)Phase 3Westwood
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast CancerPhase 3Westwood
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal CancerPhase 3Westwood
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLCPhase 1Westwood
Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic AdenocarcinomaPhase 2Westwood
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)Phase 1/2Westwood
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway AberrationsPhase 1Westwood
Study of AZD0754 in Participants With Metastatic Prostate CancerPhase 1/2Westwood
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple MyelomaPhase 2Westwood
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)Phase 3Westwood
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon CancerPhase 3Westwood
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid TumorsPhase 1/2Westwood
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple MyelomaPhase 1Westwood
SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or MesotheliomaPhase 1Westwood
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)Phase 3Westwood
The CDK4/6 Inhibitor Dosing Knowledge (CDK) StudyPhase 3Westwood
Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care ImmunotherapiesPhase 3Westwood
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)Phase 1/2Westwood
Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone MetastasisPhase 1/2Westwood
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DMPhase 3Wichita
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and ObesityPhase 3Wichita
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate CancerPhase 1Wichita
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib StudiesPhase 2Wichita
A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)Phase 3Wichita
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)Phase 3Wichita
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received ChemotherapyPhase 3Wichita
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal CancerPhase 3Wichita
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of RecurrencePhase 3Wichita
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate CancerPhase 3Wichita
A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate CancerPhase 2Wichita
A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's LymphomaPhase 1/2Wichita
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After TreatmentPhase 2Wichita
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and NivolumabPhase 3Wichita
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%Phase 3Wichita
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder CancerPhase 3Wichita
A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes MellitusPhase 3Wichita
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart FailurePhase 3Wichita
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder CancerPhase 3Wichita
ALLIANCE AVIV: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve in Failing Aortic Bioprosthetic ValvesN/AWichita
AN INTERNATIONAL, OBSERVATIONAL, BLINDED STUDY TO ASSESS THE PERFORMANCE OF THE CORDIO HEARO SYSTEM—Wichita
Abbott Cephea Mitral Valve Disease Registry—Wichita
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell TumorsPhase 3Wichita
Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at DiagnosisPhase 3Wichita
An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)Phase 1/2Wichita
Cephea Early Feasibility StudyN/AWichita
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative RhabdomyosarcomaPhase 3Wichita
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)Phase 2/3Wichita
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk NeuroblastomaPhase 3Wichita
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart FailureN/AWichita
Dose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRPPhase 2Wichita
EFS of the DUO System for Tricuspid RegurgitationN/AWichita
Global Multicenter Registry on Transcatheter TRIcuspid Valve RePLACEment—Wichita
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLyPhase 3Wichita
Maturation of Arteriovenous Fistula With Automated Sonography Assessments TrialN/AWichita
Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CICPhase 2/3Wichita
PCOM2 - The Physician Communication Intervention, Version 2.0N/AWichita
PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVRN/AWichita
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBCPhase 2Wichita
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical ProstatectomyPhase 3Wichita
Project: Every Child for Younger Patients With Cancer—Wichita
Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction CancerPhase 2Wichita
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)Phase 3Wichita
Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing ChemotherapyPhase 2Wichita
Safety and Effectiveness of the Orsiro Mission 48-mm Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery LesionsN/AWichita
Study of ALTO-300 in MDDPhase 2Wichita
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCTPhase 3Wichita
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's DiseasePhase 2Wichita
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without DiabetesPhase 2Wichita
Study of Olverembatinib (HQP1351) in Patients With CML-CPPhase 3Wichita
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)Phase 3Wichita
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney FunctionPhase 3Wichita
SuperSaturated Oxygen Comprehensive Observational Registry—Wichita
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast CancerPhase 2Wichita
Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)Phase 2Wichita
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder CancerPhase 3Wichita
Virtue® SAB in the Treatment of Coronary ISR TrialN/AWichita
Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive DisorderPhase 2Wichita

Frequently Asked Questions

How many clinical trials are recruiting in Kansas?

There are currently 521 actively recruiting clinical trials in Kansas across 36 cities.

Which cities in Kansas have the most clinical trials?

The top cities are Kansas City (246 trials), Westwood (154 trials), Overland Park (115 trials).

What conditions are being studied in Kansas?

Researchers in Kansas are studying Alzheimer's Disease, Anxiety, Arthritis, Asthma, Breast Cancer, and 12 more conditions.

What trial phases are available in Kansas?

Available phases include Phase 3 (35%), Phase 2 (20%), Not Specified (13%).

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.